WO2015181624A3 - Nucleoside derivatives for the treatment of cancer - Google Patents

Nucleoside derivatives for the treatment of cancer Download PDF

Info

Publication number
WO2015181624A3
WO2015181624A3 PCT/IB2015/000957 IB2015000957W WO2015181624A3 WO 2015181624 A3 WO2015181624 A3 WO 2015181624A3 IB 2015000957 W IB2015000957 W IB 2015000957W WO 2015181624 A3 WO2015181624 A3 WO 2015181624A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
nucleoside derivatives
compositions
compounds
Prior art date
Application number
PCT/IB2015/000957
Other languages
French (fr)
Other versions
WO2015181624A2 (en
Inventor
Cyril Dousson
David Dukhan
Christophe Claude Parsy
François-René ALEXANDRE
Rachid Rahali
Jean-Laurent Paparin
Original Assignee
Idenix Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idenix Pharmaceuticals, Inc filed Critical Idenix Pharmaceuticals, Inc
Priority to CA2947939A priority Critical patent/CA2947939A1/en
Priority to CN201580028114.XA priority patent/CN106459127A/en
Priority to MX2016015568A priority patent/MX2016015568A/en
Priority to KR1020167036090A priority patent/KR20170005492A/en
Priority to AU2015265607A priority patent/AU2015265607A1/en
Priority to EP15770630.0A priority patent/EP3149017B1/en
Priority to RU2016149761A priority patent/RU2016149761A/en
Priority to US15/313,646 priority patent/US20170101431A1/en
Priority to JP2016569379A priority patent/JP2017516779A/en
Publication of WO2015181624A2 publication Critical patent/WO2015181624A2/en
Publication of WO2015181624A3 publication Critical patent/WO2015181624A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Provided herein are compounds, compositions, and methods for the treatment of cancer, including leukemia. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents.
PCT/IB2015/000957 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer WO2015181624A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2947939A CA2947939A1 (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer
CN201580028114.XA CN106459127A (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer
MX2016015568A MX2016015568A (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer.
KR1020167036090A KR20170005492A (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer
AU2015265607A AU2015265607A1 (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer
EP15770630.0A EP3149017B1 (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer
RU2016149761A RU2016149761A (en) 2014-05-28 2015-05-27 NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASE
US15/313,646 US20170101431A1 (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer
JP2016569379A JP2017516779A (en) 2014-05-28 2015-05-27 Nucleoside derivatives for cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004006P 2014-05-28 2014-05-28
US62/004,006 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015181624A2 WO2015181624A2 (en) 2015-12-03
WO2015181624A3 true WO2015181624A3 (en) 2016-03-31

Family

ID=54196997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/000957 WO2015181624A2 (en) 2014-05-28 2015-05-27 Nucleoside derivatives for the treatment of cancer

Country Status (5)

Country Link
JP (1) JP2017516779A (en)
KR (1) KR20170005492A (en)
AU (1) AU2015265607A1 (en)
CA (1) CA2947939A1 (en)
WO (1) WO2015181624A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766917B2 (en) 2015-05-27 2020-09-08 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
KR20190065139A (en) * 2017-12-01 2019-06-11 압타바이오 주식회사 Therapeutics of blood cancer
WO2022245584A1 (en) * 2021-05-17 2022-11-24 Ligand Pharmaceuticals Incorporated Unnatural configuration nucleotide prodrug compounds
WO2023081105A1 (en) * 2021-11-02 2023-05-11 Ligand Pharmaceuticals Incorporated Cyclic phosphoramidate compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3804827A (en) * 1972-02-28 1974-04-16 Icn Pharmaceuticals 1-beta-d-arabinofuranosylcytosine-3',5'-cyclic phosphate and derivatives thereof
WO1999045935A1 (en) * 1998-03-11 1999-09-16 Lipitek International, Inc. Novel nucleoside analogs and uses in treating disease
WO2006100439A1 (en) * 2005-03-21 2006-09-28 University College Cardiff Consultants Limited Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US20080292553A1 (en) * 2005-11-09 2008-11-27 Shields Anthony F Phosphoramidate Derivatives of Fau
WO2012117246A1 (en) * 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
US20130210757A1 (en) * 2011-01-03 2013-08-15 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US20130315866A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ES8702440A1 (en) 1984-10-04 1986-12-16 Monsanto Co Prolonged release of biologically active somatotropins.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (en) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd PROLONGED LIBERATION PREPARATION
DE69719367T2 (en) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd METHOD FOR PRODUCING A COMPOSITION WITH DELAYED DELIVERY
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP2004531238A (en) 2001-02-26 2004-10-14 ファーマ パシフィック プロプライエタリー リミテッド Interferon-alpha inducible gene
ES2654064T3 (en) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
KR101339628B1 (en) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (en) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
PL2170959T3 (en) 2007-06-18 2014-03-31 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CN101910182B (en) 2007-12-28 2013-07-17 田边三菱制药株式会社 Antitumor agent
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR20210060670A (en) 2008-12-09 2021-05-26 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PE20141693A1 (en) 2011-08-01 2014-11-24 Genentech Inc METHODS TO TREAT CANCER BY THE USE OF AXIS BINDING ANTAGONISTS PD-1 AND MEK INHIBITORS

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3804827A (en) * 1972-02-28 1974-04-16 Icn Pharmaceuticals 1-beta-d-arabinofuranosylcytosine-3',5'-cyclic phosphate and derivatives thereof
WO1999045935A1 (en) * 1998-03-11 1999-09-16 Lipitek International, Inc. Novel nucleoside analogs and uses in treating disease
WO2006100439A1 (en) * 2005-03-21 2006-09-28 University College Cardiff Consultants Limited Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
US20080292553A1 (en) * 2005-11-09 2008-11-27 Shields Anthony F Phosphoramidate Derivatives of Fau
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US20130210757A1 (en) * 2011-01-03 2013-08-15 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
WO2012117246A1 (en) * 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
US20130315866A1 (en) * 2012-05-22 2013-11-28 Idenix Pharmaceuticals Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAZZANINI ET AL.: "PRODRUGS OF ARA-CMP AND ARA-AMP WITH A S-ACYL-2-THIOETHYL (SATE) BIOLABILE PHOSPHATE PROTECTING GROUP: SYNTHESIS AND BIOLOGICAL EVALUATION", NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 4/05, 1 January 1999 (1999-01-01), pages 971/972, XP009029311, ISSN: 0732-8311 *
BAZZANINI ET AL.: "Synthetic approaches to a mononucleotide prodrug of cytarabine", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, vol. 24, no. 10-12, 2005, pages 1635 - 1643, XP008141704, ISSN: 1525-7770, [retrieved on 20060816], DOI: 10.1080/15257770500267006 *
DRUMMOND ET AL.: "Deoxyribonucleoside-3',5' Cyclic Phosphates. Synthesis and Acid-Catalyzed and Enzymic Hydrolysis", J. AM. CHEM. SOC., vol. 86, no. 8, 1 April 1964 (1964-04-01), US, pages 1626 - 1630, XP055221899, ISSN: 0002-7863, DOI: 10.1021/ja01062a036 *
GOUY ET AL.: "Special feature of mixed phosphotriester derivatives of cytarabine", BIOORG. MED. CHEM., vol. 17, no. 17, 1 September 2009 (2009-09-01), pages 6340 - 6347, XP026471113, ISSN: 0968-0896, [retrieved on 20090723], DOI: 10.1016/J.BMC.2009.07.038 *
JORDHEIM ET AL.: "Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases", NATURE REVIEWS. DRUG DISCOVERY, vol. 12, no. 6, 31 May 2013 (2013-05-31), GB, pages 447 - 464, XP055221647, ISSN: 1474-1776, DOI: 10.1038/nrd4010 *
LONG ET AL.: "Synthesis and antitumor antiviral activities of 1-.beta.-D-arabinofuranosylpyrimidine 3',5'-cyclic phosphates", J. MED. CHEM., vol. 15, no. 12, 1 December 1972 (1972-12-01), US, pages 1215 - 1218, XP055221902, ISSN: 0022-2623, DOI: 10.1021/jm00282a003 *
ROBAK ET AL.: "Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases", MOLECULES, vol. 14, no. 3, 23 March 2009 (2009-03-23), pages 1183 - 1226, XP002583109, ISSN: 1420-3049, [retrieved on 20090101], DOI: 10.3390/MOLECULES14031183 *
SYMONS ET AL.: "Improved synthesis of <32>P-labelled 3',5'-cyclic AMP, 3',5'-cyclic GMP and other 3',5'cyclic ribo- and deoxyribonucletodies of high specific activity", BIOCHIMICA ET BIOPHYSICA ACTA (BBA), vol. 320, no. 2, 14 September 1973 (1973-09-14), pages 535 - 539, XP025789832, ISSN: 0304-4165, [retrieved on 19730914], DOI: 10.1016/0304-4165(73)90334-6 *
TOBIAS; BORCH: "Synthesis and Biological Evaluation of a Cytarabine Phosphoramidate Prodrug", MOLECULAR PHARMACEUTICS, vol. 1, no. 2, 2004, pages 112 - 116, XP009186775, DOI: 10.1021/mp034019v *

Also Published As

Publication number Publication date
AU2015265607A1 (en) 2016-11-17
CA2947939A1 (en) 2015-12-03
JP2017516779A (en) 2017-06-22
KR20170005492A (en) 2017-01-13
WO2015181624A2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
SI3640251T1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinoline derivatives useful in the treatment of cancer
EP3439653A4 (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
HK1256283A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
EP3297637A4 (en) Benzene-1,3,5-tricarboxamide derivatives and uses thereof
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EP3212658A4 (en) 2&#39;,2&#39;-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EP3331542A4 (en) Compositions and methods for treating cancers associated with etbr activation
MX2017002489A (en) Human therapeutic agents.
EP3166616A4 (en) Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
MX2019005349A (en) Use of sanglifehrin macrocyclic analogues as anticancer compounds.
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
EP3148526A4 (en) Use of eribulin in the treatment of cancer
EP3483166A4 (en) Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
WO2016130581A8 (en) Combination cancer therapy
EP3413906A4 (en) Cancer treatment combination compositions, methods and uses
IL248773B (en) 1,6-naphthyridine-4,5-dione derivatives and pharmaceutical compositions comprising them
TW201713323A (en) Therapeutic compositions and methods of use thereof
EP3122381A4 (en) Use of activin receptor-like kinase 1 (alk-1) antagonists in the treatment of cancer
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EP3615020A4 (en) Methods, agents, and compositions for the treatment of acute myeloid leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15770630

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2947939

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015265607

Country of ref document: AU

Date of ref document: 20150527

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15313646

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016569379

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/015568

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016027574

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015770630

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015770630

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20167036090

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016149761

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016027574

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161124